Literature DB >> 11834705

Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor.

Walter G Thomas1, Yves Brandenburger, Dominic J Autelitano, Thao Pham, Hongwei Qian, Ross D Hannan.   

Abstract

Angiotensin II (Ang II) may cause cardiac hypertrophy via type 1 Ang II receptors (AT(1)) on cardiomyocytes and through growth factors released from cardiac fibroblasts. Whereas cardiomyocyte-specific AT(1) receptor expression produces cardiac hypertrophy and remodeling in vivo, delineation of the signals that mediate growth to Ang II is challenging because the prevailing in vitro model (cultured neonatal cardiomyocytes) expresses low levels of AT(1) receptor and responds inconsistently to Ang II. In this study, when AT(1A) receptors were expressed using adenovirus in cultured neonatal cardiomyocytes, Ang II stimulated a robust hypertrophy that was not secondary to the release of cardiac fibroblast-derived factors, specifically endothelin-1. Hypertrophy was accompanied by the induction of the immediate-early response genes, c-fos and c-jun, and reexpression of atrial natriuretic peptide (ANP). Ang II-induced activation of an ANP promoter-reporter was inhibited by the dominant/negative mutants, GalphaqI and N17Ras, indicating that hypertrophic signaling by the AT(1A) receptor is via heterotrimeric G protein coupling and downstream Ras pathways. AT(1A)-mediated cardiomyocyte hypertrophy and mitogen-activated protein kinase (MAPK) activation were inhibited by the MAPK kinase inhibitor, PD98059, and the epidermal growth factor (EGF) receptor kinase antagonist, AG1478, but not by PKC inhibitor, bisindolylmaleimide-1. Moreover, Ang II-induced MAPK activation was prevented by treatment with a matrix metalloproteinase inhibitor, consistent with the tyrosine phosphorylation of the EGF receptor in response to AT(1A) receptor activation. These data unequivocally demonstrate that Ang II can directly promote cardiac myocyte growth via AT(1A) receptors expressed on these cells and reveal for the first time the important contribution of EGF receptor-transactivated MAPK signaling to this process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834705     DOI: 10.1161/hh0202.104109

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  33 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 2.  Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look.

Authors:  Timothy L Reudelhuber; Kenneth E Bernstein; Patrick Delafontaine
Journal:  Hypertension       Date:  2007-04-23       Impact factor: 10.190

3.  Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection.

Authors:  Takahisa Noma; Anthony Lemaire; Sathyamangla V Naga Prasad; Liza Barki-Harrington; Douglas G Tilley; Juhsien Chen; Philippe Le Corvoisier; Jonathan D Violin; Huijun Wei; Robert J Lefkowitz; Howard A Rockman
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

4.  G protein-coupled receptors in cardiac biology: old and new receptors.

Authors:  Simon R Foster; Eugeni Roura; Peter Molenaar; Walter G Thomas
Journal:  Biophys Rev       Date:  2015-01-13

5.  Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest.

Authors:  Richard J Mills; Drew M Titmarsh; Xaver Koenig; Benjamin L Parker; James G Ryall; Gregory A Quaife-Ryan; Holly K Voges; Mark P Hodson; Charles Ferguson; Lauren Drowley; Alleyn T Plowright; Elise J Needham; Qing-Dong Wang; Paul Gregorevic; Mei Xin; Walter G Thomas; Robert G Parton; Lars K Nielsen; Bradley S Launikonis; David E James; David A Elliott; Enzo R Porrello; James E Hudson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

6.  Endogenous endothelin 1 mediates angiotensin II-induced hypertrophy in electrically paced cardiac myocytes through EGFR transactivation, reactive oxygen species and NHE-1.

Authors:  María V Correa; Mariela B Nolly; Claudia I Caldiz; Gladys E Chiappe de Cingolani; Horacio E Cingolani; Irene L Ennis
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

7.  A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation.

Authors:  Amee J George; Brooke W Purdue; Cathryn M Gould; Daniel W Thomas; Yanny Handoko; Hongwei Qian; Gregory A Quaife-Ryan; Kylie A Morgan; Kaylene J Simpson; Walter G Thomas; Ross D Hannan
Journal:  J Cell Sci       Date:  2013-09-17       Impact factor: 5.285

Review 8.  Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

9.  Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein.

Authors:  Li Lei; Steve Mason; Dinggang Liu; Yan Huang; Carolyn Marks; Reed Hickey; Ion S Jovin; Marc Pypaert; Randall S Johnson; Frank J Giordano
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

10.  Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy.

Authors:  Tzu-Hurng Cheng; Ju-Chi Liu; Heng Lin; Neng-Lang Shih; Yen-Ling Chen; Meng-Ting Huang; Paul Chan; Ching-Feng Cheng; Jin-Jer Chen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.